SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-21-022241
Filing Date
2021-11-08
Accepted
2021-11-08 16:25:31
Documents
62
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20210930.htm   iXBRL 10-Q 1392631
2 EX-10.1 mirati-cbaumthirdamendment.htm EX-10.1 57574
3 EX-10.2 mirati-dmeekceoofferletter.htm EX-10.2 107956
4 EX-31.1 mrtx09302021ex311.htm EX-31.1 14504
5 EX-31.2 mrtx09302021ex312.htm EX-31.2 14260
6 EX-32.1 mrtx09302021ex321.htm EX-32.1 8187
12 image_1.jpg GRAPHIC 7858
  Complete submission text file 0001628280-21-022241.txt   5652326

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20210930.xsd EX-101.SCH 35852
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20210930_cal.xml EX-101.CAL 52709
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20210930_def.xml EX-101.DEF 134764
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20210930_lab.xml EX-101.LAB 431352
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20210930_pre.xml EX-101.PRE 258365
13 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20210930_htm.xml XML 880387
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 211388342
SIC: 2834 Pharmaceutical Preparations